key: cord-0989347-w4dmm0fo
authors: Rabinowich, Liane; Shibolet, Oren; Katchman, Helena
title: Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: time for comprehensive data analysis
date: 2021-10-08
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.09.037
sha: 26a04f5a63a2ffba59100c56c2f72b6887200056
doc_id: 989347
cord_uid: w4dmm0fo

nan

recently in Journal of Hepatology data from 365 liver transplant (LT) recipients receiving 2 doses of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine, reporting a positive serological response rate of 74.8 % (1) . Earlier this year we published data showing only 47.5% positive serological response in LT recipients following an identical vaccination protocol (2). This significant difference in outcomes requires discussion regarding the effectiveness of the SARS-Cov-2 vaccine in LT recipients.

Initial data regarding SARS-CoV-2 vaccination response in LT recipients was limited. A number of recently published studies add valuable information, with reported response rate ranging from 37.5% to 81% (3, 4, 5, 6, 7, 8) . Several SARS-CoV-2 vaccination studies that included LT recipients are listed in table 1. We analyzed the available data in oreder to clarify this wide response range to the vaccination. Although the response rate differs between the studies, the main factors influencing a negative serological response are consistent and include among others, age, time from transplant and the immunesuppressive regimens (1, 2) ( Table 1) .

The accumulating data supports the notion that the effectiveness of the SARS-Cov-2 vaccine results of multiple factors, related to patient and immune-suppression characteristics. To understand the influence of these factors on the vaccination outcome we compared the patient population of our study with that of Guarino et al. Some patients' characteristics such as mean age, gender, and BMI are similar between the two studies. We noted two major differences: time from transplant and immune-suppression regimen. In our group, the mean time from transplant was 6 years, compared to 14 years in the data from Guarino et al. (1, 2) . This most probably had a major impact on exposure to more intense immunesuppression, as well as other immunological processes. Another noteworthy difference is the cumulative use of immune-suppressive medications. In our study only 16.25% of the patients were on a single immune-suppressive agent, while in the data published by Guarino et al. the majority (59,7%) were treated by a single agent. Furthermore, in our study 40 patients (50%) were treated with an immune-suppressive combination that included mycophenolate mofetil (MMF), while the number was 36,2% with Guarino et al. (1, 2) .

The significant effect of immune-suppression intensity and use of MMF was also demonstrated in other studies reporting a reduced response rate to SARS-Cov-2 vaccination from 79-81% among LT patients in general to 45.5-61% among those receiving MMF (3, 4) . Preliminary results published by Del Bello et al. highlight the negative impact of age, MMF, dual and triple immune-suppression on vaccination response following a third dose of the SARS-CoV-2 vaccine (8) .

While some of the current studies lack in-depth clinical information and analysis, it is apparent that one of the most influential factors governing vaccination response is the degree of immune-suppression and use of MMF. Thus, managing immune-suppression is a major route to affect vaccine response. Currently we do not have sufficient data to recommend immune-suppression reduction for this purpose, and regardless, these decisions need to be taken on an individual patient basis. Other issues that require further assessment are long term follow-up with regards to clinical outcomes and durability of the antibody response. Given the ongoing pandemic and 3 rd vaccination booster programs, further studies with an in-depth data analysis are needed in order to guide us towards a practical recommendation on how to improve the vaccination response in the vulnerable population of LT recipients.

Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open!

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Antibody response to SARS-CoV-2 messenger RNA vaccines in liver transplant recipients

Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients-A Single-Center Experience. Vaccines (Basel)

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

J o u r n a l P r e -p r o o f (8) .J o u r n a l P r e -p r o o f † Antibody titers provided only for studies exclusive to LT recipients. † †LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescent assay (DiaSorin, Italy) ‡Anti-RBD immunoassay (Roche Elecsys) BMI= Body Mass Index, GFR= estimated glomerular filtration rate, LT=Liver Transplant, MMF= mycophenolate mofetil, SOT=Solid Organ Transplant